Please login to the form below

Not currently logged in
Email:
Password:

Symphogen

This page shows the latest Symphogen news and features for those working in and with pharma, biotech and healthcare.

Baxalta makes $1.7bn play for slice of CAR-T market

Baxalta makes $1.7bn play for slice of CAR-T market

The deal comes a few weeks after Baxalta agreed a deal with Symphogen worth up to $1.6bn to develop a series of novel checkpoint inhibitor drugs, making a bold foray

Latest news

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    Meanwhile, eyebrows were raised earlier this month when Baxalta signed a $1.6bn deal with Symphogen in oncology - which is not a major focus of either of the merging companies although

  • Baxalta inks $1.6bn immuno-oncology deal with Symphogen Baxalta inks $1.6bn immuno-oncology deal with Symphogen

    Baxalta inks $1.6bn immuno-oncology deal with Symphogen. Comes as the company's takeover negotiations with Shire continue. ... Copenhagen-based Symphogen said the first of the six candidates will start clinical testing in 2017 and that it would be

  • Merck KGaA acquires cancer drug from Symphogen Merck KGaA acquires cancer drug from Symphogen

    Merck KGaA acquires cancer drug from Symphogen. Will pay up to 495m for investigational metastatic colorectal cancer treatment. ... Merck KGgA has acquired to global rights to Symphogen's investigational cancer antibody Sym004 in a deal worth up to 495m.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    Only days before this, Baxalta had announced the investment of $175m upfront in a strategic collaboration with Symphogen taking the company into the ever popular field of oncology (headline deal value ... upfront. 1, 900. Symphogen/ Baxalta.

  • Pharma deals during September 2012 Pharma deals during September 2012

    In its search for a follow-on to Erbitux, Merck KGaA has taken an exclusive worldwide licence to Symphogen's Sym004, currently in phase I/II trials, for the treatment of ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics